Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme

NCT01822275 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT01822275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01822275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2013
Completion date
September 30, 2019
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

histologically proven diagnosis of glioblastoma or gliosarcoma (who grade iv)